Finally, its effects in T2DM are mediated by preserving insulin secretion and glycemic control through increased ATP production.<h4>Conclusion</h4>These findings reveal tissue-specific lysolecithin reprogramming in T2DM development and identify LPCAT1-mediated lysolecithin remodeling as a mechanism involved in T2DM-related endothelial and metabolic dysfunction. This evidence concerns the gene LPCAT1 and type 2 diabetes mellitus.